Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neil Munro

Showing results (11-20 of 51) with videos related to

Pageof 6
Sort By:
BMJ (Clinical Research Ed.)|February 21, 2014
Safe management of psychiatrically disturbed patients on non-psychiatric wards in the UKNicholas Moran, Neil Munro, Kirsten Lawson, et al.
BMJ (Clinical Research Ed.)|November 5, 2015
Basing approval of drugs for type 2 diabetes on real world outcomesAndrew McGovern, Robert Hinchliffe, Neil Munro, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|July 17, 2020
Does Renal Function or Heart Failure Diagnosis Affect Primary Care Prescribing for Sodium-Glucose Co-Transporter 2 Inhibitors in Type 2 Diabetes?William Hinton, Michael Feher, Neil Munro, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|April 2, 2018
Does Real World Use of Liraglutide Match its Use in the LEADER Cardiovascular Outcome Trial? Study ProtocolWilliam Hinton, Michael Feher, Neil Munro, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|March 22, 2017
Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor: Comparing Trial Data and Real-World UseAndrew McGovern, Michael Feher, Neil Munro, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|February 1, 2017
Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors: Comparing Trial and Real World Use (Study Protocol)Andrew McGovern, Michael Feher, Neil Munro, et al.
Journal of Innovation in Health Informatics|June 28, 2016
Commentary: A lack of a comparator group makes it hard to be sure whether computerised medical record system implementation achieved a better or worse outcomeSimon De Lusignan, John Williams, William Hinton, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|May 2, 2019
How Generalizable Are Cardiovascular Outcome Trials of Sodium-Glucose Co-Transporter-2 Inhibitors? A National Database Study: Study ProtocolWilliam Hinton, Michael D Feher, Neil Munro, et al.
The British Journal of General Practice : the Journal of the Royal College of General Practitioners|November 26, 2013
The predictive validity of selection for entry into postgraduate training in general practice: evidence from three longitudinal studiesFiona Patterson, Filip Lievens, Máire Kerrin, et al.
Diabetes, Obesity & Metabolism|March 23, 2019
Real-world prevalence of the inclusion criteria for the LEADER trial: Data from a national general practice networkWilliam Hinton, Michael Feher, Neil Munro, et al.
Pageof 6

Showing results (11-20 of 51) with videos related to

Sort By:
Pageof 6
BMJ (Clinical Research Ed.)|February 21, 2014
Safe management of psychiatrically disturbed patients on non-psychiatric wards in the UKNicholas Moran, Neil Munro, Kirsten Lawson, et al.
BMJ (Clinical Research Ed.)|November 5, 2015
Basing approval of drugs for type 2 diabetes on real world outcomesAndrew McGovern, Robert Hinchliffe, Neil Munro, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|July 17, 2020
Does Renal Function or Heart Failure Diagnosis Affect Primary Care Prescribing for Sodium-Glucose Co-Transporter 2 Inhibitors in Type 2 Diabetes?William Hinton, Michael Feher, Neil Munro, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|April 2, 2018
Does Real World Use of Liraglutide Match its Use in the LEADER Cardiovascular Outcome Trial? Study ProtocolWilliam Hinton, Michael Feher, Neil Munro, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|March 22, 2017
Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor: Comparing Trial Data and Real-World UseAndrew McGovern, Michael Feher, Neil Munro, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|February 1, 2017
Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors: Comparing Trial and Real World Use (Study Protocol)Andrew McGovern, Michael Feher, Neil Munro, et al.
Journal of Innovation in Health Informatics|June 28, 2016
Commentary: A lack of a comparator group makes it hard to be sure whether computerised medical record system implementation achieved a better or worse outcomeSimon De Lusignan, John Williams, William Hinton, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|May 2, 2019
How Generalizable Are Cardiovascular Outcome Trials of Sodium-Glucose Co-Transporter-2 Inhibitors? A National Database Study: Study ProtocolWilliam Hinton, Michael D Feher, Neil Munro, et al.
The British Journal of General Practice : the Journal of the Royal College of General Practitioners|November 26, 2013
The predictive validity of selection for entry into postgraduate training in general practice: evidence from three longitudinal studiesFiona Patterson, Filip Lievens, Máire Kerrin, et al.
Diabetes, Obesity & Metabolism|March 23, 2019
Real-world prevalence of the inclusion criteria for the LEADER trial: Data from a national general practice networkWilliam Hinton, Michael Feher, Neil Munro, et al.
Pageof 6